Ultrafast CT developer Imatron is beginningto experience increased demand for its high-priced CT technology.The South San Francisco, CA, vendor reported last month that revenuesskyrocketed 147% for the second quarter (end-June). Imatron recorded
Ultrafast CT developer Imatron is beginningto experience increased demand for its high-priced CT technology.The South San Francisco, CA, vendor reported last month that revenuesskyrocketed 147% for the second quarter (end-June).
Imatron recorded revenues of $7.9 million for the quarter,a marked improvement over the $3.2 million reported in the sameperiod last year. Income was also up sharply. Imatron recordednet income of $447,000, compared to a net loss of $2.7 millionin the second quarter of 1993.
Imatron shipped four Ultrafast CT scanners during the quarterand achieved several other milestones in its technology developmentprojects, according to president and CEO Lewis Meyer.
Imatron has a CT development agreement with Siemens, whichmarkets the Imatron scanner as Evolution EBT (electron-beam tomography).Imatron also operates HeartScan Imaging, which provides UltrafastCT coronary artery scanning in company-owned clinics (SCAN 4/6/94).
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.